Several models have been proposed to expand LT HCC inclusion criteria, usually based on morphological features, simple biological markers (e.g., alpha-fetoprotein—AFP), explant pathology, and/or response to locoregional therapy (LRT). The gene discussed is AFP; the disease is hepatocellular carcinoma.